Intellia reported Phase 3 success for its in vivo CRISPR therapy lonvo-z in hereditary angioedema, setting up regulatory steps toward potential FDA approval. The biotech said the therapy met its primary endpoint, reducing swelling attacks by 87% versus placebo at six months. Intellia also indicated that more than 60% of treated patients became attack-free during the study period, with no serious safety signals reported in the topline release. The company has already initiated a rolling submission with the FDA, and the program is positioned as a first-of-its-kind in vivo gene editing approach. The result strengthens the commercial and competitive narrative around in vivo CRISPR, where durability, safety, and dosing practicality are central questions for payers and clinicians. Intellia’s investors will likely track follow-on data as the FDA review proceeds. If approved, lonvo-z would become a second gene-editing medicine after Vertex’s Casgevy, extending the category from ex vivo to in vivo genome editing.